Compare Novavax Inc (NVAX) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Sezzle Inc — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while Sezzle Inc trades at $128.64 (market cap $3.95B). The key difference: Sezzle Inc is far larger — about 2.2× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Sezzle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Sezzle Inc for 15 Days on average.
| NVAX | SEZL | |
|---|---|---|
Market Cap | $1.82B | $3.95B |
Volume | 6,198,505 | 550,075 |
Sector | Health | Financials |
52-Week High | $12.56 | $188.55 |
52-Week Low | $6.22 | $50.97 |
Typical Hold Time | 59 Days | 15 Days |
Enterprise Value | $1.39B | $3.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
SEZL stock is trading at $128.64, up 12.99% in the past 24 hours, showing strong momentum with a bullish technical signal. The company demonstrates exceptional profitability with 72.36% gross margins and 30.35% net income margins, while recent earnings have consistently beaten expectations. Analyst consensus remains strongly positive with a $168 price target representing significant upside potential from current levels.
SEZL presents a compelling growth opportunity with robust financial metrics and strong analyst support, though investors should monitor competitive pressures in the BNPL sector and the stock's current technical overbought conditions. The company's expanding product portfolio and subscriber growth provide fundamental support for continued appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
